Paclitaxel

For research use only. Not for use in humans.

Catalog No.S1150 Synonyms: NSC 125973

125 publications

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Paclitaxel has been cited by 125 publications

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfPd25SUUN3ME2wMlAxODJ6NzFOwG0> NIG0enhUSU6JRWK=
LC-2-ad MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6TGlEPTB;MD6wNFA{OTdizszN MmPzV2FPT0WU
RL95-2 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJUY1KSzVyPUCuNFAxPjZ6IN88US=> M4nkTXNCVkeHUh?=
MZ1-PC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLxXpVKSzVyPUCuNFAxPzJ7IN88US=> NX7B[|U4W0GQR1XS
TE-8 NFqzbpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjxTWM2OD1yLkCwNVE4KM7:TR?= MVHTRW5ITVJ?
SW954 NIOxcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPjTWM2OD1yLkCwNVE6KM7:TR?= MlW3V2FPT0WU
TE-11 NVvmb4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP1N3ZpUUN3ME2wMlAxOTJ|IN88US=> MWjTRW5ITVJ?
PSN1 NYPlTJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHWTWM2OD1yLkCwNVMh|ryP NV\KVmVLW0GQR1XS
MOLT-4 NYnYT486T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\JZXBKSzVyPUCuNFAyPDlizszN M2riWHNCVkeHUh?=
697 M4m1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMECxOUDPxE1? NX7K[pdZW0GQR1XS
ETK-1 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC4WnRpUUN3ME2wMlAxOTV{IN88US=> NIi4O29USU6JRWK=
TE-10 NF\l[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMECxOVQh|ryP NXH6[406W0GQR1XS
HUTU-80 M3fOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLjTWM2OD1yLkCwNVY5KM7:TR?= NIjQcXFUSU6JRWK=
NTERA-S-cl-D1 NWrqfYtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMECyNFkh|ryP M1u4XXNCVkeHUh?=
MFH-ino NIXrO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMECyOlgh|ryP NWmxR4diW0GQR1XS
IA-LM M4nORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;oTWM2OD1yLkCwNlgh|ryP NHvxOlRUSU6JRWK=
MC116 NYXX[FV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33iUGlEPTB;MD6wNFI5QSEQvF2= NFzzS2pUSU6JRWK=
RKO Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXyxbm1ZUUN3ME2wMlAxOjl6IN88US=> M{nP[XNCVkeHUh?=
MRK-nu-1 NV2wd|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD1yLkCwNlk6KM7:TR?= MlTFV2FPT0WU
VA-ES-BJ NFHxZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMECzJO69VQ>? NITXRoRUSU6JRWK=
KALS-1 MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LsUGlEPTB;MD6wNFMxQCEQvF2= NFzzeIhUSU6JRWK=
BB30-HNC MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2fFZKSzVyPUCuNFA{OTRizszN MV3TRW5ITVJ?
ACN MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHYOI1EUUN3ME2wMlAxOzF4IN88US=> MUPTRW5ITVJ?
TE-9 M1z0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXS0NGl7UUN3ME2wMlAxOzJ4IN88US=> MkDYV2FPT0WU
SIG-M5 M1jBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PYNWlEPTB;MD6wNFMzPyEQvF2= MlnZV2FPT0WU
no-10 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X5emlEPTB;MD6wNFM3OiEQvF2= NFX2VYNUSU6JRWK=
EW-1 M3\WTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMECzO|Eh|ryP M2fOSnNCVkeHUh?=
SK-LMS-1 NXu5dZdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEC0NFEh|ryP M3PuUXNCVkeHUh?=
GT3TKB Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEC0N|Qh|ryP NIHiN|BUSU6JRWK=
ES4 M4XadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwMEC0OFkh|ryP M{OwUHNCVkeHUh?=
IMR-5 NF3Vb|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4joeWlEPTB;MD6wNFQ2KM7:TR?= Ml71V2FPT0WU
NCI-H1648 M{jRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDCTWM2OD1yLkCwOFY6KM7:TR?= NVfOTpJLW0GQR1XS
MV-4-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fwXGlEPTB;MD6wNFQ4PSEQvF2= MmjIV2FPT0WU
SK-UT-1 M2jG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMEC0PEDPxE1? NHnmW4xUSU6JRWK=
NB13 NFe2cIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnxbHczUUN3ME2wMlAxPDlzIN88US=> MVvTRW5ITVJ?
DJM-1 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjURnd2UUN3ME2wMlAxPTNizszN MXrTRW5ITVJ?
ES8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWz[mlYUUN3ME2wMlAxPTN6IN88US=> NV3qcpNEW0GQR1XS
TE-6 M1fpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHjSmZKSzVyPUCuNFA2PyEQvF2= MYfTRW5ITVJ?
KS-1 M3z5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HqUGlEPTB;MD6wNFU5OiEQvF2= NVLZSXk3W0GQR1XS
TE-1 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMEC2NFYh|ryP Mle1V2FPT0WU
ATN-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfWTWM2OD1yLkCwOlA6KM7:TR?= NV;pUpBLW0GQR1XS
A4-Fuk NYXHRVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rzS2lEPTB;MD6wNFYyOSEQvF2= M4\yN3NCVkeHUh?=
ALL-PO M2ThWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ERnpKSzVyPUCuNFA3OyEQvF2= NIPlZpFUSU6JRWK=
BE-13 NGTPTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PtNmlEPTB;MD6wNFY{PiEQvF2= MYPTRW5ITVJ?
KM12 MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMEC2N|ch|ryP M2PPOHNCVkeHUh?=
NOS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvHTWM2OD1yLkCwOlUh|ryP NV\JcWNjW0GQR1XS
SW962 M4Phcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH3XnhKSzVyPUCuNFA3PjJizszN M1PYRXNCVkeHUh?=
OCUB-M MonUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj6PG5KSzVyPUCuNFA3PjJizszN NGKwSXBUSU6JRWK=
NCI-H510A NEfs[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC0e4ZXUUN3ME2wMlAxPjZ3IN88US=> NY\WRXhUW0GQR1XS
EW-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2RY9CUUN3ME2wMlAxPjl2IN88US=> MUfTRW5ITVJ?
KGN MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnGflFKSzVyPUCuNFA4OTJizszN MkXWV2FPT0WU
LS-411N NGP5WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHTTWM2OD1yLkCwO|E4KM7:TR?= M{DmS3NCVkeHUh?=
Becker NHrjWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVriWYxxUUN3ME2wMlAxPzJizszN MWnTRW5ITVJ?
HC-1 M1zrR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEC3NlEh|ryP MYXTRW5ITVJ?
CESS NI\JTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z4PGlEPTB;MD6wNFc{PyEQvF2= NFqxOo1USU6JRWK=
KURAMOCHI NX7LVVQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jvZWlEPTB;MD6wNFc1QCEQvF2= NFLqZ4hUSU6JRWK=
TGBC24TKB MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTENGtrUUN3ME2wMlAxPzV{IN88US=> NWXteHpLW0GQR1XS
SW982 NFXmSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknkTWM2OD1yLkCwO|Y3KM7:TR?= MoGxV2FPT0WU
HCE-4 NV7VcXp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7jOJBJUUN3ME2wMlAxPzZ5IN88US=> M33VS3NCVkeHUh?=
LOUCY M4XUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTGSoxKSzVyPUCuNFA4PzVizszN Ml;RV2FPT0WU
8-MG-BA MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XvRWlEPTB;MD6wNFc6PiEQvF2= MVvTRW5ITVJ?
HT-144 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3kfFJSUUN3ME2wMlAxQCEQvF2= NVP1VWQ5W0GQR1XS
LXF-289 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwfm9KSzVyPUCuNFA5OThizszN MXPTRW5ITVJ?
RS4-11 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DYUGlEPTB;MD6wNFg{PiEQvF2= NF\LOm5USU6JRWK=
DEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPPWGNKSzVyPUCuNFA5PDVizszN MX;TRW5ITVJ?
OCI-AML2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrGfVJKSzVyPUCuNFA5PTJizszN MnPuV2FPT0WU
CCRF-CEM NWf1UFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTjNI5JUUN3ME2wMlAxQDdzIN88US=> MlWyV2FPT0WU
A388 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDZdFk3UUN3ME2wMlAxQDd2IN88US=> M37YdHNCVkeHUh?=
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TlbmlEPTB;MD6wNFg6OSEQvF2= NU[2SlFSW0GQR1XS
OVCAR-4 NWC5cpAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUSwRYRUUUN3ME2wMlAxQTB2IN88US=> MVXTRW5ITVJ?
NCI-H1355 NXe0bnlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nkbGlEPTB;MD6wNFkyPCEQvF2= MnW5V2FPT0WU
BL-70 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2SopKSzVyPUCuNFA6OyEQvF2= MVHTRW5ITVJ?
BL-41 M4Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fOS2lEPTB;MD6wNFk{PCEQvF2= MmHLV2FPT0WU
A101D NIHib3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHlZ|lKSzVyPUCuNFA6PiEQvF2= MnW1V2FPT0WU
HL-60 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjqPINKSzVyPUCuNFA6PjZizszN MXvTRW5ITVJ?
COR-L279 M2\EN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYewOI5RUUN3ME2wMlAxQTl7IN88US=> Mnr4V2FPT0WU
NCI-SNU-16 MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7lcI1KSzVyPUCuNFExODhizszN M4TvcHNCVkeHUh?=
Calu-6 M4e3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwMEGwNVIh|ryP NVjSdlA2W0GQR1XS
SR MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMEGwNlYh|ryP MWDTRW5ITVJ?
QIMR-WIL NWDwcXpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD3[|NTUUN3ME2wMlAyODN|IN88US=> MkLnV2FPT0WU
LB647-SCLC MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH34OmNKSzVyPUCuNFExPTFizszN MoHCV2FPT0WU
RPMI-8226 NF\5WnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PXbGlEPTB;MD6wNVExOiEQvF2= Ml\wV2FPT0WU
SK-PN-DW NVPxfVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEGxNVIh|ryP NV7LSZhYW0GQR1XS
SF268 MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HYOWlEPTB;MD6wNVE2OSEQvF2= MkT4V2FPT0WU
HD-MY-Z M1nvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizTI1HUUN3ME2wMlAyOTZ|IN88US=> NGD5NFNUSU6JRWK=
DOHH-2 NF3hVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMEGyNFMh|ryP NIjqSopUSU6JRWK=
SCC-3 NGjveolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXXWlEPTB;MD6wNVIxPCEQvF2= MYXTRW5ITVJ?
ST486 M17Mc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTMTWM2OD1yLkCxNlA1KM7:TR?= NF;VWWxUSU6JRWK=
NALM-6 NH;kOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrSUHVKSzVyPUCuNFEzOTRizszN MX3TRW5ITVJ?
NCI-H1436 M1z0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT0SmdKSzVyPUCuNFEzOzFizszN NEf5d4VUSU6JRWK=
KE-37 NYLhOm85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3UY96UUN3ME2wMlAyOjN2IN88US=> Ml7jV2FPT0WU
RPMI-8402 NX65WmJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHNTWM2OD1yLkCxNlU3KM7:TR?= MYTTRW5ITVJ?
RXF393 M{D6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPuTWM2OD1yLkCxNlU4KM7:TR?= MWrTRW5ITVJ?
KARPAS-45 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwMEGyO{DPxE1? NGXvUFNUSU6JRWK=
HOP-62 M1XaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXVXXBXUUN3ME2wMlAyOjd4IN88US=> NILVWZNUSU6JRWK=
ES1 M{\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjxRlNKSzVyPUCuNFEzQDhizszN M3;WTHNCVkeHUh?=
L-363 NXrwOHhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTBwMEGzOVEh|ryP NFjOU5FUSU6JRWK=
GI-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojuTWM2OD1yLkCxN|c{KM7:TR?= NWOxPWs6W0GQR1XS
CTV-1 MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP0TWM2OD1yLkCxOFc5KM7:TR?= M4n2VXNCVkeHUh?=
TE-5 NXu5SWxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMEG0PVYh|ryP MU\TRW5ITVJ?
SNU-C2B M3PFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rhPWlEPTB;MD6wNVQ6PiEQvF2= MmX2V2FPT0WU
K-562 NI\4XWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX36S4dwUUN3ME2wMlAyPTF4IN88US=> NUi5VZg3W0GQR1XS
SNB75 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHyw[lRKSzVyPUCuNFE2PCEQvF2= MVLTRW5ITVJ?
MOLT-13 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rJT2lEPTB;MD6wNVY{PyEQvF2= MlnpV2FPT0WU
LS-123 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDlTWM2OD1yLkCxOlY1KM7:TR?= MUfTRW5ITVJ?
NCI-SNU-5 NVroT4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXQTWM2OD1yLkCxO|AyKM7:TR?= MYHTRW5ITVJ?
Daudi NHnVeYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEG3NFgh|ryP NWjZb3hZW0GQR1XS
A253 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEG3N|gh|ryP MlrDV2FPT0WU
TGBC1TKB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NESxU2FKSzVyPUCuNFE4PTJizszN MUjTRW5ITVJ?
SJSA-1 NWrr[GRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrQTWM2OD1yLkCxO|Y4KM7:TR?= M4TsenNCVkeHUh?=
NCCIT MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjOXZNFUUN3ME2wMlAyPzZ7IN88US=> NVvzW4pOW0GQR1XS
NCI-H69 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL6dWF6UUN3ME2wMlAyPzd6IN88US=> Mny3V2FPT0WU
SH-4 M1LWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrJTWM2OD1yLkCxPFk2KM7:TR?= NYL2NZdrW0GQR1XS
HCC1187 NWHMNHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwMEG5NlQh|ryP NGPGR3ZUSU6JRWK=
HCC1599 NHX1cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMEKwNkDPxE1? Mn;xV2FPT0WU
ONS-76 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEKwN|Yh|ryP NEG2bnFUSU6JRWK=
KU812 NUTNfmo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\jTWM2OD1yLkCyNFM6KM7:TR?= MlHVV2FPT0WU
ML-2 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrKTWM2OD1yLkCyNFQ4KM7:TR?= NWnFRoZ4W0GQR1XS
HCE-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTvTWM2OD1yLkCyNFkzKM7:TR?= M1HrWnNCVkeHUh?=
NCI-H446 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3STGhKSzVyPUCuNFIyOTJizszN M{\XSXNCVkeHUh?=
RPMI-6666 NXnPeIlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnxe2twUUN3ME2wMlAzOTR7IN88US=> MnzhV2FPT0WU
MOLT-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yWIhVUUN3ME2wMlAzOTV|IN88US=> MnTGV2FPT0WU
JiyoyeP-2003 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP3doVkUUN3ME2wMlAzOTd4IN88US=> MnHIV2FPT0WU
MHH-PREB-1 M4myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTZZZlsUUN3ME2wMlAzOTlzIN88US=> MVTTRW5ITVJ?
MC-CAR NVfhNJRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPtTmtKSzVyPUCuNFI{OjZizszN M{XMUXNCVkeHUh?=
BC-3 M17ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLYTWM2OD1yLkCyN|Q1KM7:TR?= MUnTRW5ITVJ?
KINGS-1 Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD1yLkCyN|U2KM7:TR?= Mlm0V2FPT0WU
PF-382 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrXTWM2OD1yLkCyN|c5KM7:TR?= NXLqNlNsW0GQR1XS
J-RT3-T3-5 NGLieZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMEKzPFMh|ryP MkHwV2FPT0WU
SF539 NI\YTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonGTWM2OD1yLkCyOFAyKM7:TR?= M{WyVHNCVkeHUh?=
LB831-BLC NVTSNYtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoOwTWM2OD1yLkCyOFg2KM7:TR?= MYXTRW5ITVJ?
DMS-114 NIjPSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMEK1NFIh|ryP MY\TRW5ITVJ?
LB1047-RCC M1nrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LkZ2lEPTB;MD6wNlUyKM7:TR?= M{j2fnNCVkeHUh?=
LB771-HNC M17TRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxUJliUUN3ME2wMlAzPTN2IN88US=> M{PDc3NCVkeHUh?=
BB65-RCC NVK4VYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL6eI5KSzVyPUCuNFI2OzRizszN NU\0Z5N3W0GQR1XS
BV-173 NWXz[2pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmexTWM2OD1yLkCyOVU1KM7:TR?= M17Nd3NCVkeHUh?=
ARH-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHyO2d7UUN3ME2wMlAzPjBzIN88US=> M1nLfHNCVkeHUh?=
IST-MEL1 NUnPOmd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSxTWM2OD1yLkCyOlI{KM7:TR?= MnXkV2FPT0WU
NB1 NE\wfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETROVhKSzVyPUCuNFI3QDdizszN NEnTRoNUSU6JRWK=
EoL-1-cell NXT1doZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDqPXRQUUN3ME2wMlAzPjh6IN88US=> MV\TRW5ITVJ?
KY821 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInzfHRKSzVyPUCuNFI3QTdizszN NIjYTYRUSU6JRWK=
CMK MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XNe2lEPTB;MD6wNlc{PCEQvF2= NIDsS3ZUSU6JRWK=
NCI-H2126 NEHiTXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUixZoRvUUN3ME2wMlAzPzZ6IN88US=> M2HaRXNCVkeHUh?=
NCI-H526 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfOOJF7UUN3ME2wMlAzQDlzIN88US=> MYPTRW5ITVJ?
COLO-684 M1y1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj6TWM2OD1yLkCyPVA5KM7:TR?= MoPIV2FPT0WU
NCI-H747 NF7rcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3G5U2lEPTB;MD6wNlk{OyEQvF2= NWPDVpRIW0GQR1XS
JAR NEnmOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXPTWM2OD1yLkCyPVQ3KM7:TR?= MXLTRW5ITVJ?
MEG-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXKTWM2OD1yLkCyPVc5KM7:TR?= MYjTRW5ITVJ?
MONO-MAC-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTBwMEOwNlMh|ryP MX\TRW5ITVJ?
IST-SL1 M1S5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXwTWM2OD1yLkCzNFQzKM7:TR?= MV7TRW5ITVJ?
CPC-N NUe2OpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEOwO|kh|ryP MW\TRW5ITVJ?
NCI-H1963 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfIfXRUUUN3ME2wMlA{OTNzIN88US=> M4\vd3NCVkeHUh?=
K052 NIfDd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEOyOFch|ryP Mlv5V2FPT0WU
KM-H2 M2DLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLBTWM2OD1yLkCzN|A4KM7:TR?= M4\UcnNCVkeHUh?=
TE-12 NVPy[21jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvaTWM2OD1yLkCzN|A6KM7:TR?= MVjTRW5ITVJ?
TK10 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWwWmdEUUN3ME2wMlA{OzV4IN88US=> MWXTRW5ITVJ?
NMC-G1 M4PpWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEO0OVIh|ryP MlOyV2FPT0WU
no-11 M4TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PYXGlEPTB;MD6wN|Q4QCEQvF2= Mn71V2FPT0WU
NCI-H524 NInLcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMEO1Nlkh|ryP MlmxV2FPT0WU
MHH-CALL-2 NGXHeY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXvXm9KSzVyPUCuNFM2PjJizszN M{i4NHNCVkeHUh?=
GB-1 M{HsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\WPVFnUUN3ME2wMlA{PiEQvF2= M3vtUXNCVkeHUh?=
OPM-2 NVvZb4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljuTWM2OD1yLkCzOlc{KM7:TR?= MWPTRW5ITVJ?
RH-1 NWL6XJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMEO4NVkh|ryP NHvtZpRUSU6JRWK=
NCI-H64 NXO1TpJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\OS2lEPTB;MD6wN|g2PyEQvF2= Mk\lV2FPT0WU
EVSA-T NWHaNXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M364bWlEPTB;MD6wN|kzOyEQvF2= NFjkO21USU6JRWK=
KARPAS-299 NHKw[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XZSWlEPTB;MD6wN|k5KM7:TR?= NELaXXhUSU6JRWK=
MZ7-mel M2rpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M123cmlEPTB;MD6wOFA1KM7:TR?= NU\NbVVuW0GQR1XS
LB373-MEL-D MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnVNokzUUN3ME2wMlA1OTB3IN88US=> MWnTRW5ITVJ?
HEL MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMESxOEDPxE1? MkLnV2FPT0WU
SW872 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm0NlVKSzVyPUCuNFQzOSEQvF2= Mnr6V2FPT0WU
DU-4475 M4T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;QTWM2OD1yLkC0NlQ1KM7:TR?= MYXTRW5ITVJ?
IST-SL2 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PwdWlEPTB;MD6wOFI4PSEQvF2= M3\rR3NCVkeHUh?=
NCI-H82 NGnNbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\kWoJXUUN3ME2wMlA1OzB5IN88US=> MW\TRW5ITVJ?
LC4-1 M3q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7X[YZ{UUN3ME2wMlA1OzVzIN88US=> MWLTRW5ITVJ?
HDLM-2 NWT1SmptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTBwMESzPVIh|ryP M4nGOnNCVkeHUh?=
MMAC-SF MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPq[mN5UUN3ME2wMlA1PTN2IN88US=> NFX4XWFUSU6JRWK=
L-540 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3DVVZRUUN3ME2wMlA1PjN7IN88US=> NHTtTpRUSU6JRWK=
MZ2-MEL M3juc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMES3OFIh|ryP NF\6dFNUSU6JRWK=
LU-134-A NXz3fZkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMES3O|Mh|ryP MXzTRW5ITVJ?
UACC-257 NWDLbXlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPFTWM2OD1yLkC0PFQ6KM7:TR?= MlPpV2FPT0WU
NCI-H1581 M1jkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjKTWM2OD1yLkC0PVU{KM7:TR?= Ml70V2FPT0WU
NB17 M4T4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\xSpRKSzVyPUCuNFQ6PzlizszN NUjucXlNW0GQR1XS
SBC-1 NXq5c5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj4TWM2OD1yLkC1NFQzKM7:TR?= MmPZV2FPT0WU
TALL-1 M3XMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI[1OlJKSzVyPUCuNFUxPDVizszN M1XxVHNCVkeHUh?=
NCI-H1304 M{W4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEWyNFgh|ryP NYfYU2pLW0GQR1XS
NEC8 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrnTWM2OD1yLkC1Nlg3KM7:TR?= NGj6dVBUSU6JRWK=
CAL-148 NXv5fpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;LPFJ7UUN3ME2wMlA2PDN7IN88US=> M3TQOnNCVkeHUh?=
CGTH-W-1 NFzOOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7t[ndKSzVyPUCuNFU1PDlizszN MUPTRW5ITVJ?
NCI-H889 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPmXYtKSzVyPUCuNFU2QTJizszN NUXYe3ZsW0GQR1XS
GR-ST NWjvWW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHiTWM2OD1yLkC1OlIyKM7:TR?= NFToVWdUSU6JRWK=
KARPAS-422 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPWRZVKSzVyPUCuNFU3PSEQvF2= M3XyZ3NCVkeHUh?=
RPMI-8866 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;GXY5KSzVyPUCuNFU4OTJizszN Ml\rV2FPT0WU
SCLC-21H MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEW4PFQh|ryP MorqV2FPT0WU
COR-L88 M{j5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTBwMEW5Nlch|ryP NGTicoNUSU6JRWK=
LU-139 M1LlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzvTlhKSzVyPUCuNFU6QDZizszN Mor0V2FPT0WU
SF126 NU[x[mFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfLZplIUUN3ME2wMlA3OTN|IN88US=> NWO0Z2RzW0GQR1XS
NCI-H1882 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHKTWM2OD1yLkC2OFI1KM7:TR?= M{LuTHNCVkeHUh?=
EW-24 MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwME[0PFMh|ryP M4H4TnNCVkeHUh?=
CP67-MEL M3zsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofyTWM2OD1yLkC2PFEh|ryP M2HpcnNCVkeHUh?=
DG-75 M4TQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYewWmU3UUN3ME2wMlA3QDl7IN88US=> MU\TRW5ITVJ?
LOXIMVI NX7EPIsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrKUY9kUUN3ME2wMlA4ODJ6IN88US=> NXHwZYV3W0GQR1XS
HH MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEexOVch|ryP NUeze2ZxW0GQR1XS
K5 NHnkWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEeyNlYh|ryP M123OnNCVkeHUh?=
EC-GI-10 NEj1eXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDGTWM2OD1yLkC3NlU4KM7:TR?= MXfTRW5ITVJ?
SK-N-DZ MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGwOHJKSzVyPUCuNFc{ODdizszN MoTnV2FPT0WU
A3-KAW MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLVTWM2OD1yLkC3N|UyKM7:TR?= NXv5[mRoW0GQR1XS
MLMA Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vFdmlEPTB;MD6wO|Q3PSEQvF2= NGrEWY9USU6JRWK=
LB996-RCC NIXTdmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;JNGlEPTB;MD6wO|cxPyEQvF2= M{XZVXNCVkeHUh?=
OS-RC-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz5TWM2OD1yLkC3O|Q5KM7:TR?= M1\GenNCVkeHUh?=
CTB-1 Mn3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzHRnVrUUN3ME2wMlA4QDFizszN MWTTRW5ITVJ?
IST-MES1 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDOSYFKSzVyPUCuNFc6OTJizszN NFXJemZUSU6JRWK=
LS-1034 NXjRNYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rTXWlEPTB;MD6wPFA{PSEQvF2= M4nqPHNCVkeHUh?=
HT Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWTWM2OD1yLkC4NFg3KM7:TR?= MUXTRW5ITVJ?
NCI-H2141 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEixJO69VQ>? NU\kbXlvW0GQR1XS
LB2518-MEL M{[xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXofndPUUN3ME2wMlA5OTRzIN88US=> NIS1RpNUSU6JRWK=
GI-ME-N NIH4ZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDYXFJKSzVyPUCuNFg1PTJizszN NXHDRVZZW0GQR1XS
TGW MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7pTWM2OD1yLkC4OlA4KM7:TR?= NHHvfG9USU6JRWK=
SK-NEP-1 M{HhcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEi2OFEh|ryP NUD1TFd{W0GQR1XS
NOMO-1 NGrrT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjlTWM2OD1yLkC5Nlc2KM7:TR?= NWTHfYNpW0GQR1XS
ES6 M{nJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PrVWlEPTB;MD6wPVU5QSEQvF2= MUPTRW5ITVJ?
NCI-H209 M{T0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfkfWpKUUN3ME2wMlA6Pzh4IN88US=> MYfTRW5ITVJ?
GAK NI\1dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HCSWlEPTB;MD6xNFE3KM7:TR?= MYXTRW5ITVJ?
BC-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknsTWM2OD1yLkGwN|YyKM7:TR?= M{KwR3NCVkeHUh?=
KLE MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfFXIVKSzVyPUCuNVA1PDNizszN M3PUOHNCVkeHUh?=
EW-3 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[wOXJ4UUN3ME2wMlExQThizszN NIPMXWtUSU6JRWK=
NKM-1 NXXYcVhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMUGxJO69VQ>? Mn:yV2FPT0WU
D-336MG MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInJXYVKSzVyPUCuNVEzPDRizszN NHPzW2ZUSU6JRWK=
NB69 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3pdYp5UUN3ME2wMlEyOzBzIN88US=> NGG4eIZUSU6JRWK=
D-263MG NYjGdHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Nd5pKSzVyPUCuNVE4OTJizszN NHvkNpNUSU6JRWK=
KP-N-YS M4LE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfNTWM2OD1yLkGyNlkyKM7:TR?= NWDmPHRmW0GQR1XS
NCI-H1155 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\CTWM2OD1yLkGyOVU5KM7:TR?= M1vBRXNCVkeHUh?=
BOKU MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwMUK1O|kh|ryP NECwSoFUSU6JRWK=
LAMA-84 NI\qWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\GRolNUUN3ME2wMlEzQTlizszN MkLWV2FPT0WU
Raji MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LvWmlEPTB;MD6xN|EyPyEQvF2= NUHIVpN3W0GQR1XS
LU-65 NXP2fW5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XFV2lEPTB;MD6xN|MxPyEQvF2= NWXDPYlXW0GQR1XS
NCI-H187 NEiy[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4W|lEUUN3ME2wMlE{QTJ2IN88US=> NVzLc3dTW0GQR1XS
GCIY MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUS5NFEh|ryP MkDsV2FPT0WU
NCI-H2107 M{HtUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O4T2lEPTB;MD6xOVA5KM7:TR?= MWfTRW5ITVJ?
NCI-H1522 NE\jOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPDTWM2OD1yLkG1NlY3KM7:TR?= NV31blZ2W0GQR1XS
NB6 M3O4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX1TYhzUUN3ME2wMlE2PjJ|IN88US=> M1vkZ3NCVkeHUh?=
EM-2 NHm1bJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMUW3NFYh|ryP Mm\zV2FPT0WU
HCC2218 M1vXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMUW5PEDPxE1? MmKwV2FPT0WU
NCI-H748 M{fEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3y5NmlEPTB;MD6xOlM4PiEQvF2= MVvTRW5ITVJ?
MS-1 M3PNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDsTWM2OD1yLkG2OVM4KM7:TR?= M2ftUnNCVkeHUh?=
NB5 NX\3UYpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMU[1PVch|ryP NF3YWYNUSU6JRWK=
OMC-1 NHXLSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMU[2PFgh|ryP NU\QbYtqW0GQR1XS
NCI-H345 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXZTm5{UUN3ME2wMlE3QTJ6IN88US=> M4KybnNCVkeHUh?=
L-428 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vZUWlEPTB;MD6xOlk1PSEQvF2= NYizNVQ4W0GQR1XS
SCH NELJO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMUi2PFUh|ryP M4[ycHNCVkeHUh?=
NCI-H1417 NXjUeGN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDuTIRKSzVyPUCuNVkzOjdizszN M1fEU3NCVkeHUh?=
COLO-320-HSR NEjHXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjSTWM2OD1yLkG5OVMzKM7:TR?= MmTkV2FPT0WU
BT-474 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\yTWM2OD1yLkKwPFkzKM7:TR?= Mm\YV2FPT0WU
GDM-1 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIeJBwUUN3ME2wMlIyQTdzIN88US=> MXjTRW5ITVJ?
NCI-H2196 M13wbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m5TWlEPTB;MD6yNlI{PSEQvF2= Mn7jV2FPT0WU
KP-N-RT-BM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTNV2hxUUN3ME2wMlIzOzR7IN88US=> M3rrc3NCVkeHUh?=
KNS-81-FD Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDIS2lIUUN3ME2wMlIzQTV6IN88US=> NX;NXnlZW0GQR1XS
COLO-668 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y3WGlEPTB;MD6yN|Y4PSEQvF2= NWLwOnZwW0GQR1XS
C2BBe1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LEdWlEPTB;MD6yOlc1PyEQvF2= NH;GcmhUSU6JRWK=
Ramos-2G6-4C10 M3jZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXK[3FKSzVyPUCuNlY6PTRizszN M{HaNXNCVkeHUh?=
CAS-1 NUDRZ3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3[WlEPTB;MD6yO|A6PiEQvF2= Mmi3V2FPT0WU
GOTO NFPUbI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMke4PVQh|ryP MkixV2FPT0WU
LP-1 NIWwWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwMkiwOVch|ryP NVfkW4V[W0GQR1XS
NCI-SNU-1 MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwMkm0NlIh|ryP MX7TRW5ITVJ?
EB-3 MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG3TWM2OD1yLkK5PVc6KM7:TR?= M3XxT3NCVkeHUh?=
MHH-NB-11 NHfIPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4Rm1KSzVyPUCuN|A1ODJizszN MUHTRW5ITVJ?
SK-N-FI MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TvbGlEPTB;MD6zNVY6OiEQvF2= Mm\yV2FPT0WU
HCC2157 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;WSnVKSzVyPUCuN|M6OTNizszN M3qyZ3NCVkeHUh?=
SIMA Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwM{S1PFEh|ryP M{D3RXNCVkeHUh?=
MDA-MB-134-VI NX;qRW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{[5Nlgh|ryP MUnTRW5ITVJ?
NCI-H1694 NImwWoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwM{eg{txO MV\TRW5ITVJ?
EHEB NFjOZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwM{mwPFUh|ryP M1rOWHNCVkeHUh?=
U-266 M17vSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPWNFB1UUN3ME2wMlM6QDR4IN88US=> MmfPV2FPT0WU
LC-1F NH:wdZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDab4hIUUN3ME2wMlQ{PzZ3IN88US=> NY\2fJA5W0GQR1XS
SHP-77 MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwNEe4OVUh|ryP Mn\rV2FPT0WU
LS-513 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LFcGlEPTB;MD60PVMxPyEQvF2= NYrGbGdEW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973
Smiles CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)C4=CC=CC=C4)C5(O)CC(OC(=O)C(O)C(NC(=O)C6=CC=CC=C6)C7=CC=CC=C7)C(=C1C5(C)C)C

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04000906 Not yet recruiting Drug: NAB paclitaxel|Drug: Cisplatin Peritoneal Carcinomatosis University Hospital Geneva September 2019 Phase 1
NCT04046887 Not yet recruiting Drug: Lonsurf|Drug: Gemcitabine|Drug: Nab-Paclitaxel Pancreatic Cancer|Pancreatic Ductal Adenocarcinoma Patrick Joseph Loehrer Sr.|Indiana University|Taiho Oncology Inc. August 2019 Phase 1
NCT03779464 Recruiting Drug: S1 or Gemcitabine Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1 Wuhan Union Hospital China August 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID